15 09, 2021 Achieve Life Sciences to Participate in Upcoming Investor Conferencesadmin2021-09-09T13:30:32-04:00September 15th, 2021|Press Release| Read More
14 09, 2021 Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conferenceadmin2021-09-13T18:22:22-04:00September 14th, 2021|Press Release| Read More
9 09, 2021 Achieve Life Sciences to Participate in Two Upcoming Investor Conferencesadmin2021-09-07T20:47:36-04:00September 9th, 2021|Press Release| Read More
13 08, 2021 Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awardsadmin2021-08-11T19:52:14-04:00August 13th, 2021|Press Release| Read More
12 08, 2021 Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Updateadmin2021-08-11T16:41:34-04:00August 12th, 2021|Press Release| Read More
11 08, 2021 Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimenadmin2021-08-10T10:54:29-04:00August 11th, 2021|Press Release| Read More
3 08, 2021 Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021admin2021-07-15T17:04:49-04:00August 3rd, 2021|Press Release| Read More
22 07, 2021 Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Useadmin2021-07-21T15:56:56-04:00July 22nd, 2021|Press Release| Read More
29 06, 2021 Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisiniclineadmin2021-06-28T14:56:54-04:00June 29th, 2021|Press Release| Read More
3 06, 2021 Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addictionadmin2021-06-02T19:52:19-04:00June 3rd, 2021|Press Release| Read More